Neusignal Therapeutics is developing NTX-083, a novel low-molecule compound intended to treat Alzheimer’s disease via a mechanism distinct from existing therapies. The company completed a physician-initiated single-dose Phase 1 trial at the University of Tokyo Hospital (Feb–Sep 2025) and a company-sponsored multiple-dose Phase 1 trial (Nov 2025–Mar 2026) in healthy adults, with both Japanese trials reporting high safety, strong tolerability, and favorable pharmacokinetics and no significant side effects. Neusignal plans to begin a Phase 1b trial in Alzheimer’s patients in the United States later this year. The company intends to use the Series B proceeds to fund that U.S. trial and to expand its workforce ahead of potential strategic alliances with global pharmaceutical firms. Neusignal originated from Tohoku University and is headquartered in Tokyo.

Total raised

$33M

Funding rounds

1

Latest round

Series B

Latest activity

Jul 2026